Immediate-early gene expression in structures outside the basal ganglia is associated to l-DOPA-induced dyskinesia

Neurobiology of Disease

Volumn 62, Issue , 2014, Pages 179-192

  Bastide, Matthieu F ^a   Dovero, Sandra ^a   Charron, Giselle ^a   Porras, Gregory ^a   Gross, Christian E ^a   Fernagut, Pierre Olivier ^a   Bézard, Erwan ^a  

^a INSTITUT DES MALADIES NEURODÉGÉNÉRATIVES   (France)

Author keywords

Dyskinesia; IEG; L DOPA; Stereology; Whole brain

Indexed keywords

BENSERAZIDE; CITALOPRAM; DESIPRAMINE; DOPAMINE; DOPAMINE 1 RECEPTOR; LEVODOPA; TRANSCRIPTION FACTOR DELTA FOSB; TRANSCRIPTION FACTOR FRA 2;

ABNORMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARC GENE; ARTICLE; BASAL GANGLION; BRAIN NUCLEUS; BRAIN TISSUE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORPUS STRIATUM; DELTA FOSB GENE; DISEASE SEVERITY; DOPAMINE METABOLISM; DOPAMINERGIC TRANSMISSION; DYSKINESIA; FRA2 GENE; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; HABENULA; HIPPOCAMPUS; IMMEDIATE EARLY GENE; LONG TERM CARE; MALE; MOTOR CORTEX; NONHUMAN; PEDUNCULOPONTINE TEGMENTAL NUCLEUS; PONTINE NUCLEUS; PRIORITY JOURNAL; PROTEIN STRUCTURE; RAT; STEREOLOGY; STIMULUS RESPONSE; STRIA TERMINALIS; STRIATE CORTEX; SUBSTANTIA NIGRA PARS RETICULATA; TISSUE STRUCTURE; TREATMENT OUTCOME; ZIF268 GENE; ZONA INCERTA;

DYSKINESIA; IEG; L-DOPA; STEREOLOGY; WHOLE BRAIN;

ANIMALS; ANTIPARKINSON AGENTS; BASAL GANGLIA; BRAIN; CYTOSKELETAL PROTEINS; DYSKINESIA, DRUG-INDUCED; EARLY GROWTH RESPONSE PROTEIN 1; FOS-RELATED ANTIGEN-2; IMMEDIATE-EARLY PROTEINS; LEVODOPA; MALE; NERVE TISSUE PROTEINS; PROTO-ONCOGENE PROTEINS C-FOS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84886263429     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2013.09.020     Document Type: Article

References (71)

1. Andersson M., et al. Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol. Dis. 1999, 6:461-474.
2. Bastian A.J. Learning to predict the future: the cerebellum adapts feedforward movement control. Curr. Opin. Neurobiol. 2006, 16:645-649.
3. Bernard R., Veh R.W. Individual neurons in the rat lateral habenular complex project mostly to the dopaminergic ventral tegmental area or to the serotonergic raphe nuclei. J. Comp. Neurol. 2012, 520:2545-2558.
4. Berthet A., et al. Pharmacological analysis demonstrates dramatic alteration of D1 dopamine receptor neuronal distribution in the rat analog of l-DOPA-induced dyskinesia. J. Neurosci. 2009, 29:4829-4835.
5. Berthet A., et al. l-DOPA impairs proteasome activity in parkinsonism through D1 dopamine receptor. J. Neurosci. 2012, 32:681-691.
6. Bezard E., et al. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat. Rev. Neurosci. 2001, 2:577-588.
7. Bostan A.C., et al. The basal ganglia communicate with the cerebellum. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:8452-8456.
8. Brodal P. The pontocerebellar projection in the rhesus monkey: an experimental study with retrograde axonal transport of horseradish peroxidase. Neuroscience 1979, 4:193-208.
9. Brodal P. The projection from the nucleus reticularis tegmenti pontis to the cerebellum in the rhesus monkey. Exp. Brain Res. 1980, 38:29-36.
10. Buck K., Ferger B. Intrastriatal inhibition of aromatic amino acid decarboxylase prevents l-DOPA-induced dyskinesia: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine lesioned rats. Neurobiol. Dis. 2008, 29:210-220.
11. Carta M., Bezard E. Contribution of pre-synaptic mechanisms to l-DOPA-induced dyskinesia. Neuroscience 2011, 198:245-251.
12. Carta M., et al. Role of striatal l-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats. J. Neurochem. 2006, 96:1718-1727.
13. Carta M., et al. Dopamine released from 5-HT terminals is the cause of l-DOPA-induced dyskinesia in parkinsonian rats. Brain 2007, 130:1819-1833.
14. Carta M., et al. Involvement of the serotonin system in l-DOPA-induced dyskinesias. Parkinsonism Relat. Disord. 2008, 14(Suppl. 2):S154-S158.
15. Carta M., et al. Serotonin-dopamine interaction in the induction and maintenance of l-DOPA-induced dyskinesias. Prog. Brain Res. 2008, 172:465-478.
16. Cenci M.A., Konradi C. Maladaptive striatal plasticity in l-DOPA-induced dyskinesia. Prog. Brain Res. 2010, 183:209-233.
17. Cenci M.A., et al. l-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur. J. Neurosci. 1998, 10:2694-2706.
18. Cenci M.A., et al. Changes in the regional and compartmental distribution of FosB- and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic l-DOPA treatment. Neuroscience 1999, 94:515-527.
19. Cenci M.A., et al. Animal models of neurological deficits: how relevant is the rat?. Nat. Rev. Neurosci. 2002, 3:574-579.
20. Ebihara K., et al. Differential expression of FosB, c-Fos, and Zif268 in forebrain regions after acute or chronic l-DOPA treatment in a rat model of Parkinson's disease. Neurosci. Lett. 2011, 496:90-94.
21. Engeln M., et al. Reinforcing properties of Pramipexole in normal and parkinsonian rats. Neurobiol. Dis. 2012, 49C:79-86.
22. Fahn S. How do you treat motor complications in Parkinson's disease: medicine, surgery, or both?. Ann. Neurol. 2008, 64(Suppl. 2):S56-S64.
23. Feyder M., et al. l-DOPA-induced dyskinesia and abnormal signaling in striatal medium spiny neurons: focus on dopamine D1 receptor-mediated transmission. Front. Behav. Neurosci. 2011, 5:71.
24. Fiorentini C., et al. Loss of synaptic D1 dopamine/N-methyl-d-aspartate glutamate receptor complexes in l-DOPA-induced dyskinesia in the rat. Mol. Pharmacol. 2006, 69:805-812.
25. Freedman L.J., Cassell M.D. Distribution of dopaminergic fibers in the central division of the extended amygdala of the rat. Brain Res. 1994, 633:243-252.
26. Geisler S., Trimble M. The lateral habenula: no longer neglected. CNS Spectr. 2008, 13:484-489.
27. Granado N., et al. D1 but not D5 dopamine receptors are critical for LTP, spatial learning, and LTP-Induced arc and zif268 expression in the hippocampus. Cereb. Cortex 2008, 18:1-12.
28. Guigoni C., et al. Levodopa-induced dyskinesia in MPTP-treated macaques is not dependent on the extent and pattern of nigrostrial lesioning. Eur. J. Neurosci. 2005, 22:283-287.
29. Guigoni C., et al. Involvement of sensorimotor, limbic, and associative basal ganglia domains in l-3,4-dihydroxyphenylalanine-induced dyskinesia. J. Neurosci. 2005, 25:2102-2107.
30. Gundersen H.J., Jensen E.B. The efficiency of systematic sampling in stereology and its prediction. J. Microsc. 1987, 147:229-263.
31. Halje P., et al. Levodopa-induced dyskinesia is strongly associated with resonant cortical oscillations. J. Neurosci. 2012, 32:16541-16551.
32. Hasue R.H., Shammah-Lagnado S.J. Origin of the dopaminergic innervation of the central extended amygdala and accumbens shell: a combined retrograde tracing and immunohistochemical study in the rat. J. Comp. Neurol. 2002, 454:15-33.
33. Herkenham M., Nauta W.J. Afferent connections of the habenular nuclei in the rat. A horseradish peroxidase study, with a note on the fiber-of-passage problem. J. Comp. Neurol. 1977, 173:123-146.
34. Hikosaka O., et al. Habenula: crossroad between the basal ganglia and the limbic system. J. Neurosci. 2008, 28:11825-11829.
35. Hong S., Hikosaka O. The globus pallidus sends reward-related signals to the lateral habenula. Neuron 2008, 60:720-729.
36. Jenner P. Molecular mechanisms of l-DOPA-induced dyskinesia. Nat. Rev. Neurosci. 2008, 9:665-677.
37. Krawczyk M., et al. Double-dissociation of the catecholaminergic modulation of synaptic transmission in the oval bed nucleus of the stria terminalis. J. Neurophysiol. 2011, 105:145-153.
38. Krawczyk M., et al. D1 dopamine receptor-mediated LTP at GABA synapses encodes motivation to self-administer cocaine in rats. J. Neurosci. 2013, 33:11960-11971.
39. Loebrich S., Nedivi E. The function of activity-regulated genes in the nervous system. Physiol. Rev. 2009, 89:1079-1103.
40. Lundblad M., et al. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur. J. Neurosci. 2002, 15:120-132.
41. Meissner W., et al. Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine. Neurobiol. Dis. 2006, 22:586-598.
42. Meloni E.G., et al. Behavioral and anatomical interactions between dopamine and corticotropin-releasing factor in the rat. J. Neurosci. 2006, 26:3855-3863.
43. Miguelez C., et al. Locus coeruleus and dorsal raphe neuron activity and response to acute antidepressant administration in a rat model of Parkinson's disease. Int. J. Neuropsychopharmacol. 2011, 14:187-200.
44. Navailles S., et al. Serotonergic neurons mediate ectopic release of dopamine induced by l-DOPA in a rat model of Parkinson's disease. Neurobiol. Dis. 2010, 38:136-143.
45. Navailles S., et al. Chronic l-DOPA therapy alters central serotonergic function and l-DOPA-induced dopamine release in a region-dependent manner in a rat model of Parkinson's disease. Neurobiol. Dis. 2011, 41:585-590.
46. Okuno H. Regulation and function of immediate-early genes in the brain: beyond neuronal activity markers. Neurosci. Res. 2011, 69:175-186.
47. Olsson M., et al. Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J. Neurosci. 1995, 15:3863-3875.
48. Phelix C.F., et al. Monoamine innervation of bed nucleus of stria terminalis: an electron microscopic investigation. Brain Res. Bull. 1992, 28:949-965.
49. Pioli E.Y., et al. Differential behavioral effects of partial bilateral lesions of ventral tegmental area or substantia nigra pars compacta in rats. Neuroscience 2008, 153:1213-1224.
50. Porras G., et al. PSD-95 expression controls l-DOPA dyskinesia through dopamine D1 receptor trafficking. J. Clin. Invest. 2012, 122:3977-3989.
51. Putterman D.B., et al. Evaluation of levodopa dose and magnitude of dopamine depletion as risk factors for levodopa-induced dyskinesia in a rat model of Parkinson's disease. J. Pharmacol. Exp. Ther. 2007, 323:277-284.
52. Rangel-Barajas C., et al. l-DOPA-induced dyskinesia in hemiparkinsonian rats is associated with up-regulation of adenylyl cyclase type V/VI and increased GABA release in the substantia nigra reticulata. Neurobiol. Dis. 2011, 41:51-61.
53. Rolland A.S., et al. Evidence for a dopaminergic innervation of the pedunculopontine nucleus in monkeys, and its drastic reduction after MPTP intoxication. J. Neurochem. 2009, 110:1321-1329.
54. Rolland A.S., et al. Internal pallidum and substantia nigra control different parts of the mesopontine reticular formation in primate. Mov. Disord. 2011, 26:1648-1656.
55. Rylander D., et al. Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. Ann. Neurol. 2010, 68:619-628.
56. Schmitz C., Hof P.R. Recommendations for straightforward and rigorous methods of counting neurons based on a computer simulation approach. J. Chem. Neuroanat. 2000, 20:93-114.
57. Schuster S., et al. The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor lovastatin reduces severity of l-DOPA-induced abnormal involuntary movements in experimental Parkinson's disease. J. Neurosci. 2008, 28:4311-4316.
58. + channel reduces development of abnormal involuntary movement in the rat model of l-3,4-dihydroxyphenylalanine-induced dyskinesia. Biol. Psychiatry 2009, 65:518-526.
59. Sgambato-Faure V., et al. Coordinated and spatial upregulation of arc in striatonigral neurons correlates with l-DOPA-induced behavioral sensitization in dyskinetic rats. J. Neuropathol. Exp. Neurol. 2005, 64:936-947.
60. Slomianka L., West M.J. Estimators of the precision of stereological estimates: an example based on the CA1 pyramidal cell layer of rats. Neuroscience 2005, 136:757-767.
61. Stocchi F., et al. Strategies for treating patients with advanced Parkinson's disease with disastrous fluctuations and dyskinesias. Clin. Neuropharmacol. 1997, 20:95-115.
62. Takakusaki K., et al. Basal ganglia efferents to the brainstem centers controlling postural muscle tone and locomotion: a new concept for understanding motor disorders in basal ganglia dysfunction. Neuroscience 2003, 119:293-308.
63. Thach W.T., et al. The cerebellum and the adaptive coordination of movement. Annu. Rev. Neurosci. 1992, 15:403-442.
64. Timmann D., et al. The human cerebellum contributes to motor, emotional and cognitive associative learning. A review. Cortex 2010, 46:845-857.
65. Valastro B., et al. Expression pattern of JunD after acute or chronic l-DOPA treatment: comparison with deltaFosB. Neuroscience 2007, 144:198-207.
66. Watabe-Uchida M., et al. Whole-brain mapping of direct inputs to midbrain dopamine neurons. Neuron 2012, 74:858-873.
67. West M.J., et al. Unbiased stereological estimation of the total number of neurons in thesubdivisions of the rat hippocampus using the optical fractionator. Anat. Rec. 1991, 231:482-497.
68. West M.J., et al. Hippocampal neurons in pre-clinical Alzheimer's disease. Neurobiol. Aging 2004, 25:1205-1212.
69. Westin J.E., et al. Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of l-DOPA-induced dyskinesia and the role of dopamine D1 receptors. Biol. Psychiatry 2007, 62:800-810.
70. Wirtshafter D. Rotation and immediate-early gene expression in rats treated with the atypical D1 dopamine agonist SKF 83822. Pharmacol. Biochem. Behav. 2007, 86:505-510.
71. Wu T., Hallett M. The cerebellum in Parkinson's disease. Brain 2013, 136:696-709.